Votum Labs raises €1.2M to push its labs into Europe and Mexico
What's the deal? Spanish biotech Votum Labs has closed a €1.2 million early-stage round at a €10.01 million post-money valuation. The round, backed by family offices from the Región de Murcia, will fund international expansion, research and new product launches.
What does Votum do? Founded in 2021 by Alejandro Martí and Borja Vera, the Murcia-based lab develops science-backed products across two lines: human health and veterinary care. Its lead brand, Cronidol, is sold in more than 2,000 Spanish pharmacies.
Where's the money going? Votum will split the capital across internationalisation (35%), marketing (25%), product and R&D (22%), and hiring (18%). It also plans new brands and in-house projects such as Myovo, BIORCAN, and BIOSTEOCAN.
What's the endgame? Votum wants to replicate its commercial model in Europe and Mexico through an omnichannel strategy spanning pharmacy, specialised distribution, and veterinary clinics. Cronidol is already expanding in Romania, Portugal, and Mexico.
What could go wrong? The round is modest, and Votum's headline numbers remain company projections. It reports 74.1% compound annual growth between 2022 and 2025 and expects €935,000 in 2026 revenue — figures that are yet to prove durable international traction.
The signal: Healthtech was among Spain's most active funding sectors in Q3 2026, but recent large deals have favoured capital-intensive biotech and medtech. Votum's small round is less a major sector financing than a commercial-scale test of whether a cannabinoid-origin business can scale through pharmacy and veterinary channels abroad.
Read more: elreferente.es
Image credit: Votum World
